Limited Approval Expected for Mentor Corp. Drug:...
- Share via
From Times Staff and Wire Reports
Limited Approval Expected for Mentor Corp. Drug: The Santa Barbara company said the FDA has indicated that its Urethrin drug will be approved to treat male post-prostatectomy incontinence. But a Mentor officer said the company was “shocked” at the FDA’s refusal to grant the same status to the drug for use in female incontinence--the largest potential market for the drug. Mentor’s stock dropped $6.875 a share to close at $19.375.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
